Study of GS-3242 in Participants With HIV-1; Substudy-05
← catalyst calendarSponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
27actual
Sites
28
Countries
Mexico, Thailand, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-29 | actual | When the study began enrolling |
| Primary completion | 2026-03-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-16 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- HIV-1-infection
Interventions
- Drug: GS-3242
- Drug: BVY — also filed as Biktarvy®
- Drug: Standard of Care
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo Data
measured Baseline, Day 11
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed